Single Agent Ibrutinib (PCI-32765)
Farooqui M, Aue G, Valdez J, et al.
Key Points:
Data on first 53 patients in Phase II, single-center prospective trial of ibrutinib monotherapy in DEL 17p CLL
Estimated event free survival (14 mo): 93%
At 6 months: PR: 66%; PR with lymphocytosis (PRL): 28%
80% of pts had decrease in relative size of DEL 17p subclone; 4 pts (20%) had no evidence of 17p after 6 mo
Adverse events: diarrhea, fatigue, arthralgias/myalgias, and rash
Non hematologic toxicities grade ≥3 occurred in <5%, grade ≥3 infections or cytopenias: 15%
Implications:
- Ibrutinib as single agent appears to be equally effective against CLL with or without DEL 17p
View the original abstract on the ASH website.
